Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1

Molecular Therapy

Volumn 18, Issue 2, 2010, Pages 285-294

  Hardcastle, Jayson ^a,b   Kurozumi, Kazuhiko ^a   Dmitrieva, Nina ^a   Sayers, Martin P ^a,b   Ahmad, Sarwat ^b   Waterman, Peter ^c   Weissleder, Ralph ^c   Chiocca, E Antonio ^a   Kaur, Balveen ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRAIN ANTIGEN; ONCOLYTIC VIRUS; THROMBOSPONDIN 1; THROMBOSPONDIN 2; UNCLASSIFIED DRUG; VASCULOSTATIN 120; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CELL DENSITY; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; GLIOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; INNATE IMMUNITY; MICROVASCULATURE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENIC PROTEINS; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; GLIOMA; HUMANS; MICE; MICE, NUDE; ONCOLYTIC VIRUSES; SIMPLEXVIRUS; VERO CELLS;

HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS;

EID: 76349108532     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.232     Document Type: Article

References (50)

1. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Narayana, A, Kelly, P, Golfnos, J, Parker, E, Johnson, G, Knopp, E, et al. (2009). Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110: 173-180.
3. Shah, AC, Benos, D, Gillespie, GY and Markert, JM (2003). Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 65: 203-226.
4. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117.
5. Haseley, A, Alvarez-Breckenridge, C, Chaudhury, AR and Kaur, B (2009). Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov 4: 1-13.
6. Choudhary, A, Hiscott, P, Hart, CA, Kaye, SB, Batterbury, M and Grierson, I (2005). Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes. Mol Vis 11: 163-168.
7. Lee, S, Zheng, M, Kim, B and Rouse, BT (2002). Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest 110: 1105-1111.
8. Leibovich, SJ, Polverini, PJ, Fong, TW, Harlow, LA and Koch, AE (1994). Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci USA 91: 4190-4194.
9. Zheng, M, Deshpande, S, Lee, S, Ferrara, N and Rouse, BT (2001). Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 75: 9828-9835.
10. Biswas, PS and Rouse, BT (2005). Early events in HSV keratitis\-setting the stage for a blinding disease. Microbes Infect 7: 799-810.
11. Aghi, M, Rabkin, SD and Martuza, RL (2007). Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specifc viral mutations or by administering a thrombospondin- derived peptide. Cancer Res 67: 440-444.
12. Kurozumi, K, Hardcastle, J, Thakur, R, Shroll, J, Nowicki, M, Otsuki, A, et al. (2008). Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16: 1382-1391.
13. Grote, K, Salguero, G, Ballmaier, M, Dangers, M, Drexler, H and Schieffer, B (2007). The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. Blood 110: 877-885.
14. de Fraipont, F, Nicholson, AC, Feige, JJ and Van Meir, EG (2001). Thrombospondins and tumor angiogenesis. Trends Mol Med 7: 401-407.
15. Kaur, B, Brat, DJ, Devi, NS and Van Meir, EG (2005). Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 24: 3632-3642.
16. Babic, AM, Kireeva, ML, Kolesnikova, TV and Lau, LF (1998). CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 95: 6355-6360.
17. Monnier, Y, Farmer, P, Bieler, G, Imaizumi, N, Sengstag, T, Alghisi, GC, et al. (2008). CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 68: 7323-7331.
18. Koh, JT, Kook, H, Kee, HJ, Seo, YW, Jeong, BC, Lee, JH, et al. (2004). Extracellular fragment of brain-specifc angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking alphavbeta5 integrin. Exp Cell Res 294: 172-184.
19. Nishimori, H, Shiratsuchi, T, Urano, T, Kimura, Y, Kiyono, K, Tatsumi, K, et al. (1997). A novel brain-specifc p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15: 2145-2150.
20. Kaur, B, Cork, SM, Sandberg, E, Devi, NS, Zhang, Z, Klenotic, PA, et al. (2009). Vasculostatin, a 120kDa BAI1 fragment can effciently inhibit intracranial angiogenesis and tumorigenesis, despite a proangiogenic stimulus. Cancer Res 69: 1212-1220.
21. Mullen, JT, Donahue, JM, Chandrasekhar, S, Yoon, SS, Liu, W, Ellis, LM, et al. (2004). Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 101: 869-877.
22. Liu, TC, Zhang, T, Fukuhara, H, Kuroda, T, Todo, T, Canron, X, et al. (2006). Dominant-negative fbroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 12: 6791-6799.
23. Liu, TC, Zhang, T, Fukuhara, H, Kuroda, T, Todo, T, Martuza, RL, et al. (2006). Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced effcacy. Mol Ther 14: 789-797.
24. Bonnefoy, A, Moura, R and Hoylaerts, MF (2008). The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 65: 713-727.
25. Mahller, YY, Vaikunth, SS, Ripberger, MC, Baird, WH, Saeki, Y, Cancelas, JA, et al. (2008). Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 68: 1170-1179.
26. Terada, K, Wakimoto, H, Tyminski, E, Chiocca, EA and Saeki, Y (2006). Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 13: 705-714.
27. Sundaresan, P, Hunter, WD, Martuza, RL and Rabkin, SD (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 74: 3832-3841.
28. Todo, T, Feigenbaum, F, Rabkin, SD, Lakeman, F, Newsome, JT, Johnson, PA, et al. (2000). Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2: 588-595.
29. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M, et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
30. Kaur, B, Brat, DJ, Calkins, CC and Van Meir, EG (2003). Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 162: 19-27.
31. de Visser, KE, Eichten, A and Coussens, LM (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
32. Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G, et al. (2007). Effect of tumor microenvironment modulation on the effcacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781.
33. Fulci, G, Dmitrieva, N, Gianni, D, Fontana, EJ, Pan, X, Lu, Y, et al. (2007). Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 67: 9398-9406.
34. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J, et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878. (Pubitemid 44298654)
35. Kunstfeld, R, Hirakawa, S, Hong, YK, Schacht, V, Lange-Asschenfeldt, B, Velasco, P, et al. (2004). Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin infammation associated with persistent lymphatic hyperplasia. Blood 104: 1048-1057.
36. Oura, H, Bertoncini, J, Velasco, P, Brown, LF, Carmeliet, P and Detmar, M (2003). A critical role of placental growth factor in the induction of infammation and edema formation. Blood 101: 560-567.
37. Libertini, S, Iacuzzo, I, Perruolo, G, Scala, S, Ieranò, C, Franco, R, et al. (2008). Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 14: 6505-6514.
38. Zohrabian, VM, Nandu, H, Gulati, N, Khitrov, G, Zhao, C, Mohan, A, et al. (2007). Gene expression profling of metastatic brain cancer. Oncol Rep 18: 321-328.
39. Hatanaka, H, Oshika, Y, Abe, Y, Yoshida, Y, Hashimoto, T, Handa, A, et al. (2000). Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specifc angiogenesis inhibitor 1 (BAI1). Int J Mol Med 5: 181-183.
40. Nam, DH, Park, K, Suh, YL and Kim, JH (2004). Expression of VEGF and brain specifc angiogenesis inhibitor-1 in glioblastoma: prognostic signifcance. Oncol Rep 11: 863-869.
41. Lee, JH, Koh, JT, Shin, BA, Ahn, KY, Roh, JH, Kim, YJ, et al. (2001). Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. Int J Oncol 18: 355-361.
42. Fukushima, Y, Oshika, Y, Tsuchida, T, Tokunaga, T, Hatanaka, H, Kijima, H, et al. (1998). Brain-specifc angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. Int J Oncol 13: 967-970.
43. Kang, X, Xiao, X, Harata, M, Bai, Y, Nakazaki, Y, Soda, Y, et al. (2006). Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Ther 13: 385-392.
44. Kudo, S, Konda, R, Obara, W, Kudo, D, Tani, K, Nakamura, Y, et al. (2007). Inhibition of tumor growth through suppression of angiogenesis by brain-specifc angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 18: 785-791.
45. Park, D, Tosello-Trampont, AC, Elliott, MR, Lu, M, Haney, LB, Ma, Z, et al. (2007). BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450: 430-434.
46. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
47. Hudziak, RM, Lewis, GD, Winget, M, Fendly, BM, Shepard, HM and Ullrich, A (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172.
48. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD, et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874.
49. Montet, X, Figueiredo, JL, Alencar, H, Ntziachristos, V, Mahmood, U and Weissleder, R (2007). Tomographic fuorescence imaging of tumor vascular volume in mice. Radiology 242: 751-758.
50. Choi, WW, Lewis, MM, Lawson, D, Yin-Goen, Q, Birdsong, GG, Cotsonis, GA, et al. (2005). Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 18: 143-152.